Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2017
March 27 2017 - 4:01PM
Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small
molecule drug conjugates (SMDCs) and companion imaging agents for
personalized therapy, today announced that eight posters will be
presented by Endocyte scientists at the American Association for
Cancer Research (AACR) Annual Meeting 2017 to be held in
Washington, DC, April 1 - 5, 2017.
Key presentations during the meeting include a late-breaking
poster presentation of new research from investigators and faculty
at the Purdue University Center for Drug Discovery on the
application of Endocyte's SMDC technology in a chimeric antigen
receptor (CAR) therapy setting. Additionally, the company will
present several posters with preclinical data relating to
Endocyte’s SMDC technology, including developments in combination
therapies and novel proPBD warheads.
The presentation materials will be available on Endocyte’s
website following presentation at the conference.
Presentations are as follows:
Abstract #: |
|
|
2057 |
Title: |
|
|
Evaluation of anti-tumor efficacy of EC1456 in low-passage and
pre-treated patient-derived xenograft models of triple-negative
breast cancer |
When: |
|
|
Monday, April 3, 1 p.m. – 5 p.m. CDT |
Session Title: |
|
|
Drug Resistance: Other Topics |
Location: |
|
|
Halls A-C, Poster Section 3 |
|
|
|
|
|
|
|
|
Abstract #: |
|
|
2133 |
Title: |
|
|
Pre-clinical studies of EC2629, a highly potent FR targeted
DNA crosslinking agent |
When: |
|
|
Monday, April 3, 1 p.m. – 5 p.m. CDT |
Session Title: |
|
|
New Targets 2 |
Location: |
|
|
Halls A-C, Poster Section 6 |
|
|
|
|
|
|
|
|
Abstract #: |
|
|
LB-187 |
Title: |
|
|
New methods for controlling CAR T-cell mediated cytokine
storms |
When: |
|
|
Tuesday, April 4, 8 a.m. – 12 p.m. CDT |
Session Title: |
|
|
Late-Breaking Research: Immunology |
Location: |
|
|
Poster Section 35 |
|
|
|
|
|
|
|
|
Abstract #: |
|
|
3670 |
Title: |
|
|
Treatment of epithelial ovarian cancer with folate receptor
(α/β) targeted chemotherapy is enhanced by CTLA-4 blockage:
Learning from animal models |
When: |
|
|
Tuesday, April 4, 8 a.m. – 12 p.m. CDT |
Session Title: |
|
|
Dendritic Cells as Critical Immune Targets |
Location: |
|
|
Halls A-C, Poster Section 27 |
|
|
|
|
|
|
|
|
Abstract #: |
|
|
3228 |
Title: |
|
|
Development and characterization of in vitro assays to detect
and quantitate tubulysin B hydrazide in biological samples |
When: |
|
|
Tuesday, April 4, 8 a.m. – 12 p.m. CDT |
Session Title: |
|
|
Novel Molecular Targets 2 |
Location: |
|
|
Halls A-C, Poster Section 8 |
|
|
|
|
|
|
|
|
Abstract #: |
|
|
4017 |
Title: |
|
|
Development and application of an immunohistochemistry-based
assay for evaluating functional and accessible folate receptor
expression in vivo |
When: |
|
|
Tuesday, April 4, 1 p.m. – 5 p.m. CDT |
Session Title: |
|
|
Assay Technology |
Location: |
|
|
Halls A-C, Poster Section 1 |
|
|
|
|
|
|
|
|
Abstract #: |
|
|
4574 |
Title: |
|
|
Combinatorial strategies of folate receptor-targeted
chemotherapy guided by improved understanding of tumor
microenvironment and immunomodulation |
When: |
|
|
Tuesday, April 4, 1 p.m. – 5 p.m. CDT |
Session Title: |
|
|
Clinical Immunotherapy, Viruses, and bacteria |
Location: |
|
|
Halls A-C, Poster Section 25 |
|
|
|
|
|
|
|
|
Abstract #: |
|
|
5147 |
Title: |
|
|
Novel warheads for targeted therapies of cancer: The concept
and design of proPBDs |
When: |
|
|
Wednesday, April 5, 8 a.m. – 12 p.m. CDT |
Session Title: |
|
|
Novel Drug Delivery Technology |
Location: |
|
|
Halls A-C, Poster Section 5 |
About Endocyte's SMDC Bi-Specific Adaptors
Endocyte's SMDC bi-specific adaptors represent a novel approach
that makes possible the engineering of a single universal CAR
T-cell, designed to bind with high affinity to fluorescein
isothiocyanate (FITC). This universal CAR T-cell can be
specifically directed to cancer cells through the administration of
a tumor targeted FITC-containing SMDC, known as a bi-specific
adaptor that acts to bridge the universal CAR T-cell with the
cancer cells to cause localized T-cell activation. This
approach has been shown pre-clinically to address three key CAR
T-cell issues by: (i) avoiding hyper-activation of CAR T-cells
leading to a cytokine storm, (ii) enabling termination of CAR
T-cell activity upon eradication of the tumor, and (iii)
potentially enabling elimination of all cancer cells in
heterogeneous solid tumors. In March 2017, Endocyte entered
into a research collaboration with Seattle Children's Research
Institute and Dr. Michael Jensen for the development of Endocyte's
SMDC platform in the chimeric antigen receptor T-cell (CAR T-cell)
immunotherapy setting through the use of Endocyte's proprietary
SMDC bi-specific adaptor molecules.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing
targeted therapies for the treatment of cancer and other serious
diseases. Endocyte uses its proprietary drug conjugation
technology to create novel SMDCs and companion imaging agents for
personalized targeted therapies. The company's SMDCs actively
target receptors that are over-expressed on diseased cells,
relative to healthy cells. This targeted approach is designed
to enable the treatment of patients with highly active drugs at
greater doses, delivered more frequently and over longer periods of
time than would be possible with the untargeted drug alone.
The companion imaging agents are designed to identify patients
whose disease over-expresses the target of the therapy and who are
therefore more likely to benefit from treatment. For additional
information, please visit Endocyte's website at
www.endocyte.com.
Contacts:
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, stephanie@sternir.com
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Apr 2024 to May 2024
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From May 2023 to May 2024